Trial Profile
Effect of Sunitinib or Sorafenib as Neoadjuvant therapy in Patient with Renal Cell Carcinoma with Tumor Thrombus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 11 Jul 2018 New trial record